LYEL vs. WVE, MAZE, IMTX, AMLX, IMNM, TRML, NUVB, TRVI, ARDX, and CVAC
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include WAVE Life Sciences (WVE), Maze Therapeutics (MAZE), Immatics (IMTX), Amylyx Pharmaceuticals (AMLX), Immunome (IMNM), Tourmaline Bio (TRML), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Ardelyx (ARDX), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs. Its Competitors
Lyell Immunopharma (NASDAQ:LYEL) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.
Lyell Immunopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.37, indicating that its share price is 237% less volatile than the S&P 500.
WAVE Life Sciences has higher revenue and earnings than Lyell Immunopharma. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by company insiders. Comparatively, 24.0% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, WAVE Life Sciences had 5 more articles in the media than Lyell Immunopharma. MarketBeat recorded 7 mentions for WAVE Life Sciences and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.01 beat WAVE Life Sciences' score of 0.71 indicating that Lyell Immunopharma is being referred to more favorably in the media.
WAVE Life Sciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. WAVE Life Sciences' return on equity of -78.45% beat Lyell Immunopharma's return on equity.
Lyell Immunopharma currently has a consensus price target of $15.00, suggesting a potential downside of 11.76%. WAVE Life Sciences has a consensus price target of $20.33, suggesting a potential upside of 158.37%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Lyell Immunopharma.
Summary
WAVE Life Sciences beats Lyell Immunopharma on 12 of the 16 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 10/16/2025 by MarketBeat.com Staff
